ALBANY, N.Y., May 9, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI)
today announced that it has hired Louis
Yu, Ph.D., to fill the newly created position of senior vice
president of quality and compliance. Dr. Yu will report to
William S. Marth, AMRI's president
and CEO. Dr. Yu will oversee all aspects of quality and cGMP
compliance at all divisions of AMRI, including Drug Discovery
Services, API and Drug Product development and manufacturing.
"AMRI has an outstanding reputation for quality service, and as
we continue to expand our global network, it is critical that we
continue to build on that reputation with our customers," said Mr.
Marth. "Louis' deep quality experience at a number of
pharmaceutical companies – both generic and branded – gives him the
understanding of what our customers need. In addition, as AMRI
grows toward our goal of achieving $1
billion in annual revenues by 2018, robust accountability
for quality is an important business need. Louis is a welcome
addition to our team."
Dr. Yu comes to AMRI with over 30 years of leadership experience
in the quality and R&D functions of branded and generic
pharmaceutical companies. Most recently, he served as executive
vice president, global quality & compliance for Perrigo, a
manufacturer of private label and branded OTC and generic Rx
pharmaceutical products. There, he was responsible for strategic
leadership and management of the global quality function. He led
traditional quality and regulatory compliance as well as the global
patient safety/medical affairs department. Prior to that, he served
as vice president of quality for CV Therapeutics, now a division of
Gilead. Earlier in his career, he served as the most senior quality
leader at Forest Laboratories, Solvay Pharmaceuticals and Par
Pharmaceutical as well as with increasing level of responsibilities
in the quality and R&D organizations of the J&J
Companies.
About AMRI
Albany Molecular Research Inc. (AMRI) is a
global contract research and manufacturing organization that has
been working with the Life Sciences industry to improve patient
outcomes and the quality of life for more than two decades. With
locations in North America,
Europe and Asia, our key business segments include
Discovery and Development Services (DDS), Active Pharmaceutical
Ingredients (API), and Drug Product Manufacturing (DPM). Our DDS
segment provides comprehensive services from hit identification to
IND, including expertise with diverse chemistry, library design and
synthesis, in vitro biology and pharmacology, drug metabolism and
pharmacokinetics, as well as natural products. API supports the
chemical development and cGMP manufacture of complex API, including
potent and cytotoxic compounds, controlled substances, steroids,
peptides, hormones, and sterile API. DPM supports development
through commercial scale production of complex liquid-filled and
lyophilized parenterals, sterile suspensions and ophthalmic
formulations. For more information about AMRI, please visit our
website at www.amriglobal.com or follow us on Twitter
(@amriglobal).
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amri-appoints-louis-yu-phd-as-senior-vice-president-quality-and-compliance-300264818.html
SOURCE AMRI